Evidence map›Paper›PMID 25692462›Full record

ArticleBioconjugate chemistry2015

Multivalent site-specific phage modification enhances the binding affinity of receptor ligands.

Jaymes Beech, Lana Saleh, Julie Frentzel, Heidi Figler, Ivan R Corrêa, Brenda Baker, Caroline Ramspacher, Melissa Marshall, Siva Dasa, Joel Linden and 2 more

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jaymes Beech
Lana Saleh#Division of Chemical Biology, New England Biolabs, Ipswich, Massachusetts 01938, United States.
Julie Frentzel#Division of Chemical Biology, New England Biolabs, Ipswich, Massachusetts 01938, United States.
Heidi Figler
Ivan R Corrêa#Division of Chemical Biology, New England Biolabs, Ipswich, Massachusetts 01938, United States.
Brenda Baker#Division of Chemical Biology, New England Biolabs, Ipswich, Massachusetts 01938, United States.
Caroline Ramspacher#Division of Chemical Biology, New England Biolabs, Ipswich, Massachusetts 01938, United States.
Melissa Marshall
Siva Dasa
Joel Linden⊥La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, United States.
Christopher J Noren#Division of Chemical Biology, New England Biolabs, Ipswich, Massachusetts 01938, United States.
Kimberly A Kelly
New England Biolabs (United States) · USLa Jolla Institute for Immunology · US

Funding

BIOTECHNOLOGY TRAINING PROGRAMT32GM008715 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LAURIE, GORDON WILLIAM · 2000 to 2019
$6.6M
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivoR01EB010023 · NIBIB · UNIVERSITY OF VIRGINIA · PI EL-BARDEESY, NABEEL, KELLY, KIMBERLY A. · 2010 to 2013
$1.4M
NIBIB NIH HHS R01 EB010023NIBIB NIH HHS R01EB010023NIGMS NIH HHS T32 GM008715NIGMS NIH HHS T32 GM08715
6 · The paper itself

Abstract

High-throughput screening of combinatorial chemical libraries is a powerful approach for identifying targeted molecules. The display of combinatorial peptide libraries on the surface of bacteriophages offers a rapid, economical way to screen billions of peptides for specific binding properties and has impacted fields ranging from cancer to vaccine development. As a modification to this approach, we have previously created a system that enables site-specific insertion of selenocysteine (Sec) residues into peptides displayed pentavalently on M13 phage as pIII coat protein fusions. In this study, we show the utility of selectively derivatizing these Sec residues through the primary amine of small molecules that target a G protein-coupled receptor, the adenosine A1 receptor, leaving the other coat proteins, including the major coat protein pVIII, unmodified. We further demonstrate that modified Sec-phage with multivalent bound agonist binds to cells and elicits downstream signaling with orders of magnitude greater potency than that of unconjugated agonist. Our results provide proof of concept of a system that can create hybrid small molecule-containing peptide libraries and open up new possibilities for phage-drug therapies.

Indexed as

AnimalsBacteriophage M13Binding SitesCHO CellsCricetinaeCricetulusHumansLigandsProtein BindingReceptor, Adenosine A1LigandsReceptor, Adenosine A1

Identifiers

PMID25692462
PMCPMC6252250
OpenAlexW2092787742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.